SOPHHealthcare · Health Information ServicesThe 5 Wall Street analysts covering SOPHiA GENETICS SA hold a median 12-month price target of $9 — +29.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 69 of 100 as at 3 Nov 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores SOPHiA GENETICS SA on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (94): The shares have been drifting up relative to others.
Value (22): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on SOPH, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +29.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Oct 2026 | HC Wainwright & Co. | Reiterates | Buy | $14 |
| 5 Aug 2026 | BTIG | Maintains | Buy | $8.00 → $9.00 |
| 5 Aug 2026 | BTIG | Maintains | Buy | — |
| 5 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $12 → $14 |
| 5 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 20 July 2026 | HC Wainwright & Co. | Initiates | Buy | $12 |
| 20 July 2026 | HC Wainwright & Co. | Initiates | Buy | — |
| 15 June 2026 | BTIG | Reiterates | Buy | — |
| 15 June 2026 | BTIG | Reiterates | Buy | $8.00 |
| 6 May 2026 | BTIG | Reiterates | Buy | — |
| 15 Apr 2026 | BTIG | Maintains | Buy | — |
| 26 Jan 2026 | Guggenheim | Maintains | Buy | — |
| 10 Nov 2025 | BTIG | Maintains | Buy | — |
| 18 Dec 2024 | Craig-Hallum | Initiates | Buy | — |
| 7 Aug 2024 | RBC Capital | Maintains | Outperform | — |
| 27 June 2024 | Guggenheim | Initiates | Buy | — |
| 6 Mar 2024 | BTIG | Maintains | Buy | — |
| 6 Mar 2024 | RBC Capital | Reiterates | Outperform | — |
| 12 Jan 2024 | RBC Capital | Reiterates | Outperform | — |
| 29 Nov 2023 | RBC Capital | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
SOPH appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, SOPHiA GENETICS SA returned +48.9% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 91% of US stocks
Cheaper than 18% of US stocks
Cheaper than 13% of US stocks
Cheaper than 84% of US stocks
Higher than 76% of US stocks
Higher than 65% of US stocks
Higher than 78% of US stocks
Higher than 14% of US stocks
Higher than 6% of US stocks
Higher than 13% of US stocks
Higher than 17% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
SOPHiA GENETICS SA has a market value of $588.2M and an enterprise value of $542.4M.
Revenue in the twelve months to 30 June 2026: $86.2M. The latest quarter grew 27.2% year on year.
Net income over the same four quarters: −$80.9M, a −93.9% net margin.
Diluted earnings per share, trailing twelve months: $−1.15.
Free cash flow in the twelve months to 30 June 2026: −$50.5M, after $9.2M of capital spending.
SOPHiA GENETICS SA spent $0.0 on dividends in the twelve months to 30 June 2026.
Trailing P/E: −5.9×; forward P/E: −13.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
SOPHiA GENETICS SA employs 415 people — $208K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own SOPHiA GENETICS SA — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha published the transcript of SOPHiA GENETICS SA’s Q3 2026 earnings call. The excerpt provides no details about the discussion.
Why it matters — The transcript may be relevant to SOPH watchers seeking information from the company’s quarterly earnings call, but the excerpt does not disclose its contents.
SOPHiA GENETICS reported Q3 2026 revenue growth of 25% year over year, citing U.S. expansion, liquid biopsy adoption and biopharma collaborations. It narrowed its adjusted EBITDA loss and expects full-year revenue at the upper end of its prior guidance range.
Why it matters — The update provides SOPH watchers with information on revenue growth, loss reduction and the company’s full-year revenue outlook.
SOPHiA GENETICS reported a quarterly loss of $0.24 per share, greater than the Zacks consensus estimate of a $0.13 loss. The loss was narrower than the $0.30 per share loss reported a year earlier.
Why it matters — SOPH watchers may note that the reported per-share loss exceeded the consensus estimate, although it improved from a year earlier.
SOPHiA GENETICS reported third-quarter 2026 revenue of $24.3 million, up 25% year over year, and a net loss of $20.3 million. It expects full-year revenue at the upper end of its previously issued $94 million to $96 million guidance range, while noting foreign-exchange movements could weigh on fourth-quarter revenue if sustained.
Why it matters — The results update gives SOPH watchers information on quarterly growth, losses, adjusted EBITDA performance, and the company's revenue outlook.
SOPHiA GENETICS said it will report third-quarter 2026 financial results before U.S. markets open on November 3, 2026. The company will host a conference call at 8:00 a.m. that day to discuss the results and business outlook.
Why it matters — SOPH watchers can note the date and time when the company plans to share its quarterly results and business outlook.
The 5 Wall Street analysts covering SOPHiA GENETICS SA have a median 12-month price target of $9, with estimates ranging from $7 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering SOPHiA GENETICS SA, 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks SOPHiA GENETICS SA 69 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Nov 2026, SOPHiA GENETICS SA ranks 69 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (94 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +29.1% from the last close, and Ticker Nerd's factor model ranks SOPHiA GENETICS SA 69 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering SOPHiA GENETICS SA publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SOPH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $14 over the next 12 months.
SOPHiA GENETICS SA returned +48.9% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
SOPHiA GENETICS SA Ordinary Shares is the equity of SOPHiA GENETICS, a healthcare technology company focused on data-driven medicine and life sciences research. The company develops cloud-native software that analyzes complex genomic and multimodal healthcare data, helping hospitals, laboratories, and biopharmaceutical organizations generate actionable insights across cancer, rare disorders, and other diagnostic areas.
The most recent item we track (Seeking Alpha, 3 Nov 2026): "SOPHiA GENETICS SA (SOPH) Q3 2026 Earnings Call Transcript". Seeking Alpha published the transcript of SOPHiA GENETICS SA’s Q3 2026 earnings call. The excerpt provides no details about the discussion.
SOPHiA GENETICS SA Ordinary Shares is the equity of SOPHiA GENETICS, a healthcare technology company focused on data-driven medicine and life sciences research. The company develops cloud-native software that analyzes complex genomic and multimodal healthcare data, helping hospitals, laboratories, and biopharmaceutical organizations generate actionable insights across cancer, rare disorders, and other diagnostic areas. Its core platform, SOPHiA DDM, supports the interpretation of data from multiple testing modalities, including genomics, radiomics, clinical information, biological data, and digital pathology. SOPHiA GENETICS serves a global network of healthcare and research institutions that use its software to streamline analysis and support more coordinated diagnostic workflows. Headquartered in Rolle, Switzerland, SOPHiA GENETICS operates at the intersection of healthcare, artificial intelligence, and precision medicine, making it an important provider of digital tools for modern clinical and research environments.
CEO Mr. Ross Jordan Muken B.Sc. · 415 employees · Switzerland · https://www.sophiagenetics.com
